Pfizer COVID-19 vaccine sales plunge 25% after new government guidance

Pfizer’s COVID-19 vaccine sales have fallen sharply, with U.S. sales of its Comirnaty shots dropping 25% after federal regulators narrowed recommendations on who should get vaccinated. Experts cite declining public interest, anti-vaccine sentiment, and confusion over updated guidance as major factors.

Source ABC

The CDC recently stopped broadly recommending COVID-19 boosters for everyone, leaving the choice up to individuals. Some pharmacies began requiring prescriptions or additional health screenings, causing uncertainty for both customers and insurers.

As a result, Pfizer reported that Comirnaty sales dropped to $870 million last quarter, down from $1.6 billion in the same period last year. Analysts expect demand to remain weak unless confidence in vaccination programs is restored.